Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

118.04USD
23 Feb 2018
Change (% chg)

$0.49 (+0.42%)
Prev Close
$117.55
Open
$118.82
Day's High
$119.20
Day's Low
$115.71
Volume
157,375
Avg. Vol
184,579
52-wk High
$153.58
52-wk Low
$112.15

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $5,100.63
Shares Outstanding(Mil.): 43.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-United Therapeutics Corp Reports Qtrly EPS Of $0.43

* Q4 EARNINGS PER SHARE VIEW $3.89, REVENUE VIEW $421.7 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

Feb 21 2018

BRIEF-United Therapeutics Settles Patent Litigation With Actavis Laboratories FL

* UNITED THERAPEUTICS ANNOUNCES SETTLEMENT OF PATENT LITIGATION WITH ACTAVIS LABORATORIES FL, INC. RELATING TO ORENITRAM

Feb 15 2018

BRIEF-Celularity Announces Formation Of Co With $250 Mln In Funding From Celgene, United Therapeutics, Others

* ‍CELULARITY ANNOUNCES $250 MILLION IN FUNDING TO DELIVER TREATMENTS FOR CANCER, INFLAMMATORY AND DEGENERATIVE DISEASES, AND FUNCTIONAL REGENERATION​

Feb 15 2018

BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs

* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS

Jan 03 2018

United Therapeutics to pay $210 million to resolve U.S. kickback probe

BOSTON United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

Dec 20 2017

UPDATE 2-United Therapeutics to pay $210 mln to resolve U.S. kickback probe

BOSTON, Dec 20 United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

Dec 20 2017

United Therapeutics to pay $210 mln to resolve U.S. kickback probe

BOSTON, Dec 20 United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

Dec 20 2017

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

Nov 14 2017

BRIEF-United Therapeutics Corp reports third quarter 2017 financial results

* United Therapeutics Corporation reports third quarter 2017 financial results

Oct 25 2017

BRIEF-United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

* United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

Oct 23 2017

Earnings vs. Estimates